Member Info for GIVMESUNSHINE

Hi All - I must admit its hard to work out how much cash CEG are has / using at the moment - discontinued operations, sale proceeds etc - current operations and$ 0.5 million retained as restricted cash collateral for the OFF-1 performance bond - (which could well be on its way back to CEG) ? I think at worst there may be a need for a small bridging loan

Hi Interestking

Good post - I think its an unbelivieably good deal for CEG - on top of paying 100% of 3D's Chevron are effectively covering 80% of the drill costs upto a max drill project cost of $100 million - 60/(40 -50%). so a $50 mill Drill CEG would have to stump up $10 million. All that and retaining 40% upto drill bit point makes this a huge gift IMO..Chevrom willing to chuck that much at it for 60% im amazed to is still at these levels TBH

Apologies - put that post on by accident - ponit was - CEG have $12.3 and a free carry only needing to pay 25% of drill costs.

Whereas Chevron will ha ve to spend a total of $110 million for thier 60% to the same point of progress on first drill. I think it shows how keen they are to get thier hand on OOF 1 with OFF 3 still to come. This is much cheaper at 17p today , than it was at 12p yesterday. That big mark up was justified big not quite bought into yet ... Think this will rerate quite a bit ..

Hi All

So chevron will willing to commit upto vvv miliion

US$12.5 million cash on completion of the Transaction

Upto $37 million on 3D campaign - up $21 Million for thier share and US$15 million net of CEG 40%.

Upto $60 Million Should Chevron drill will carry 50% of CEG Uruguay's share of costs associated with that well, up to a maximum of US$20 million net to CEG Uruguay.

I like this bit

'Sondrel solved a problem that others could not, and that was necessary for the finished product, so it played a pretty significant role,' the insider told MailOnline.

Redx and Jazz have a longstanding collaborative relationship: prior targeted oncology deals cover JZP815, a precision pan-RAF inhibitor now in Phase I, and a MAPK pathway collaboration. Under these three deals, Redx could be eligible for remaining potential milestones of up to c $1.2bn. Separately, Redx has a fibrosis partnership with AstraZeneca.

Here you go

https://www.trinitydelta.org/research-notes/up-to-870m-kras-deal-marks-third-jazz-collaboration/

Summary of trniity update today

Trinity Delta view: The Jazz KRAS deal covers an under the radar programme only recently disclosed by Redx, further underscoring the strength of its medicinal chemistry expertise in discovering differentiated small molecules that address hard to drug targets in oncology and fibrosis. Business development activities also contribute non-dilutive funding, in this case extending the cash runway into 2025, beyond 2024 catalysts, thus allowing optionality around value creation from the highly attractive ROCK portfolio. Key H124 catalysts include: (1) zelasudil Phase IIa idiopathic pulmonary fibrosis data, and potential lift of the FDA partial clinical hold; (2) initiation of the first RXC008 Phase I fibrostenotic Crohn’s disease trial; and (3) topline Phase II PORCUPINE and PORCUPINE2 data for RXC004 in combination with checkpoint inhibitors in Wnt-ligand dependent cancers. Our last published valuation was £367m/$441m, or 94p per share, which does not include this latest KRAS deal with Jazz.

Hi - New to FUM, just researching - good point about amazon 4k+ sold each month now on amazon alone.

I think its far to early to call on both Cirt and certainly PSE- anyone kicking off about PSE Sales clearly has no idea.. 40-50 IN Dec month isnt bad for a soft launch, meaningful numbers will come from deals with insurers and charities etc.. Barriers are completely different to CIRT which is in the middle of a life or death process..

Its interesting to note how the SP has reacted over the last year - back in August CIRT numbers we presented and SP didnt move a jot - Announcement of the the PSE test (which holders were fully aware was coming) and the SP went mental with AIM Punters alone- follow up to the dissapointing numbers (which i also felt a little tricked by) and suddently cirt and PSE doesnt work , needs more trials, going bankbupt etc etc .. it does make you wonder who buys these shares and the power the AIM moronic herd have over the SP - 50%+ Held by institutions and they havent done anything notifible post results. I think the result exposed Jon shortcomings as a CEO, Alot has lead has been executed very well - PSE Developement, Coding , BUPA, LAB ..Thes are impressive on the ops front , Anyone who held and AIM bio know you can sit around for year waiting for Medicare code.. and beaten thier own targets .. but weve seen that Jon's style is to show us what he wants and obscure what he doesnt - He didnt lie, but he chooses to skip over data - for example at the time of placing he gave a additional figure for the numbers of tests completed - now we can see that it included July, but he didnt provide the specific date.. If he had that metality with SD etc he wont last to the. Unlike most AIMs of this Cap well have big holders who effectively form the majotiy shareholding .. so if he p=sses them about with Bull then he out of a job - or will get a pay cut , they have to vote for it.. what we say is irrelevant.. but TBH nothing fundamental has changed from 10p-50p and todays 15p price.. Other than the RNS PSE, MEDICARE CODE, BUPA DEAL and LAB cert -Q2 Funding has been stated very clearly.. no smoke and mirrors there

Now its gone quiet , it worth looking calmly at the plans going forwards

If you dig further into the accounts H2 "only" used £3 mllion of cash compared to £5.3 Million in H1 , There are some big numbers in there for the placing financing costs also - offset by the £800k recieved for PACT. Revune wise less than 100 -150 CIRT tests made their way into the accounts. I know thats not exactly good, but ingoring the post year CIRT, Cash used (which is the only figure that counts) was better than I expected.

Year End 5.2 million and with the sales as they are and placing costs absorbed, cash burn at current levels is about £3.6- 4.0 million H1

I suspect OBD are working on a smalish placing in leau of PSE CIRT and Farming out the other two -With no growth in sales £5 million would easily see out this finacial year.. theres too much evolving too do a big placing at this point intime.. My guess 15-17p and that will come from the 50% + intutional holders , its a small amount and makes sence to both holders and the company

Shes got 30,000 followers.

We are thrilled to share a groundbreaking development from the opening day of the Precision Medicine World Conference (PMWC) 2024 on January 24th. Oxford BioDynamics Plc presented their cutting-edge liquid biopsy test, the EpiSwitch® Prostate Screening Test (PSE), which is set to transform prostate cancer detection.

Combining the PSE with traditional PSA screening, the accuracy of prostate cancer risk assessment skyrockets from 55% to an impressive 94%. This leap in diagnostic precision offers a beacon of hope for reducing the high rate of false positives associated with PSA tests alone, empowering patients and doctors with confidence in their treatment decisions.

🔬 Why It Matters:

Prostate cancer is the second most common cancer among men. The PSE test's ability to accurately distinguish high-risk cases allows for a more targeted approach, prioritizing immediate treatment or monitoring, thereby avoiding unnecessary invasive procedures.

💡 Behind the Innovation:

Oxford BioDynamics, a pioneer in personalized healthcare, leverages their proprietary EpiSwitch® platform to analyze circulating chromosome conformation signatures (CCSs). This approach not only enhances screening accuracy but does so rapidly, minimally invasively, and cost-effectively.

🌍 Availability and Impact:

Now available in the United States and the UK, the PSE test has undergone extensive validation, promising to redefine the approach to prostate cancer screening and management.

🧬 The Science of 3D Genomics:

At the heart of Oxford BioDynamics' breakthroughs is the exploration of 3D Genomics, emphasizing the crucial role of the genome's 3D configuration in gene regulation.

This innovative perspective opens new avenues for diagnosing diseases, predicting therapeutic responses, and improving health outcomes.

Jp Morgan was an event the OBD was part of .. Investor event for the industry ..it's was put on LinkedIn .. no big deal either way .. as someone mentioned earlier the biggest form of misinformation comes from himself , both positive or negative. Buy high sell low - aim gambler IMO

Dug can't even read a basic RNS .. several times now .. agenda goes from ultra bull to ultra bear in aa matter of minutes - he's a fool IMO

Exactly - Great post, as we all know PSE is performed Post PSA data you can't have the test without it - there score is needed to be submitted with the test. By definition almost everyone who has this test will be high risk, Focusing on high risk group is been made very clear all along. Further validation for low risk is something that will come .. but not top spending priority IMO -

Exactly - Great post, as we all know PSE is performed Post PSA data you can't have the test without it - there score is needed to be submitted with the test. By definition almost everyone who has this test will be high risk, Focusing on high risk group is been made very clear all along. Further validation for low risk is something that will come .. but not top spending priority IMO -

Dug

Don't get me wrong -I'm not defending that ramptastic presentation .. plenty of thing I'm not happy with .. However BUPA is not one of them .. I think you are way off the mark .. it's not patent or oncologist that are going to request the test .. not yet .. it's the insurers job to make sure when a oncolgist summits a recommendation for ICI they have a formal process in place to ensure - 1) tick box - has the patient been offered Cirt 2) Cirt completed etc .Cirt result . Recommendation etc .. a process is need to be captured for the insurer and oncologist .. First stage will be to brief what's coming .. then implement it., metrics put in place etc etc .. obviously this is only an opinion, not sure what you expected happen in 10 weeks. From signature ??? The RNS stated pretty clearly that patients being referred will be offered the test .. but there will be a sequence of works both internal to BUPA and OBD to get to the point.. in not suprised investor relation don't reply if you can't see that ;0)

Hi Dug

Again - we are not targeting low risk cancer screening - we are targeting high risk area as part of diagnosis validation - only method suitable for high risk screening that comes close to PSE is MRI. You are only quoting the bit you want to read .. we are looking to get between the PSA and the MRI / Boipsy Market that's the value in the PSE. Facts haven't changed .. it's been public for a year

Hi Krull

Yes agree, I think the 97 stands out as the one that was the fluke. Till Oct over the 6 months period it's rising - nov / dec are thanksgiving and Xmas holiday periods , but even so was not impressive -if I was being over fair .. month on month isn't a statistic to live and die on .. but that 70%!jump in June was the one that raised expectations so much - over the year tests were up 600% - and all that vital evidence for the case file is being produced. I do support a lot of what Jon has done and the strategy.. and it's import to realise this rose 400% of the back of PSE launch - nothing to do with CIRT - that info was in the domain long before .. If you bought in on PSE news then everything has gone very well - coded and lab certified I super quick time .. to my mind I will look more carefully at what is not said going forward.. No update after the June high was deliberate and unprofessional IMO - He did state back then that he was looking forward to update in Jan - but coupled with rampy words has only left disproportion disappointment and loss of credibility in CEO, but to balance - The technical / physical deliverable and BUPA over the period have been impressive .. what to do on the AIM ?

Dug

You seem to want to re write words fit your changing narrative. the paper .. it say nothing of the sort .. read the conclusion word by word. PSE is suitable for screening of High Risk Groups and significantly better the PSA . It requires further validation low risk groups. PSA is t suitable for either. Are you suggesting Jon should sit on his backside and ask shareholder for 20mil to fund a 3 year trial, non revenue driving trail This is not a drug and even life and death cancer drugs are tested on a few thousand .. real world Case file is the stated strategy for a long time

With regard to BUPA -They are an insurance company - they do not have single owned hospitals or oncologist. So what they need to do is get the information/ process for claiming the test to these oncologists, the oncologist can't give the test to everyone only BUPA so things will need to be put in place and they are huge organisation did you honestly think they would sign a deal 10 weeks ago? Plus Jon stated back in May that they were working with one of the UK largest insurers - when the deal is signed he DID NOT expect any immediate revenue .. I 100%!was disappointed with Cirt numbers but I have no idea why you change your mind on everything in one go